Risk-Reducing Appendectomy and the Elimination of BRCA1 -Associated Intraperitoneal Cancer | Breast Cancer | JAMA Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Ford D, Easton DF, Stratton M,  et al; Breast Cancer Linkage Consortium.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families.  Am J Hum Genet. 1998;62(3):676-6899497246PubMedGoogle ScholarCrossref
2.
Pichert G, Jacobs C, Jacobs I,  et al.  Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers.  Fam Cancer. 2010;9(3):313-31920300867PubMedGoogle ScholarCrossref
3.
Buys SS, Partridge E, Black A,  et al; PLCO Project Team.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.  JAMA. 2011;305(22):2295-230321642681PubMedGoogle ScholarCrossref
4.
Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.  Gynecol Oncol. 2005;97(2):476-48215863147PubMedGoogle ScholarCrossref
5.
Eisen A, Lubinski J, Klijn J,  et al.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.  J Clin Oncol. 2005;23(30):7491-749616234515PubMedGoogle ScholarCrossref
6.
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk-reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.  J Natl Cancer Inst. 2009;101(2):80-8719141781PubMedGoogle ScholarCrossref
7.
Levine DA, Argenta PA, Yee CJ,  et al.  Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.  J Clin Oncol. 2003;21(22):4222-422714615451PubMedGoogle ScholarCrossref
8.
Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA. Cancer incidence in a population of Jewish women at risk of ovarian cancer.  J Clin Oncol. 2002;20(6):1570-157711896106PubMedGoogle ScholarCrossref
9.
Dalrymple JC, Bannatyne P, Russell P,  et al.  Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study of 31 cases.  Cancer. 1989;64(1):110-1152731107PubMedGoogle ScholarCrossref
10.
Saluja M, Kenwright DN, Keating JP. Pseudomyxoma peritonei arising from a mucinous borderline ovarian tumour: case report and literature review.  Aust N Z J Obstet Gynaecol. 2010;50(4):399-40320716272PubMedGoogle ScholarCrossref
11.
Domchek SM, Friebel TM, Garber JE,  et al.  Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.  Breast Cancer Res Treat. 2010;124(1):195-20320180014PubMedGoogle ScholarCrossref
12.
Powell CB, Kenley E, Chen LM,  et al.  Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.  J Clin Oncol. 2005;23(1):127-13215625367PubMedGoogle ScholarCrossref
13.
Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women.  Gynecol Oncol. 2002;87(1):52-5612468342PubMedGoogle ScholarCrossref
14.
Shi C, Hruban RH. Intraductal papillary mucinous neoplasm.  Hum Pathol. 2012;43(1):1-1621777948PubMedGoogle ScholarCrossref
15.
Ban S, Naitoh Y, Mino-Kenudson M,  et al.  Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.  Am J Surg Pathol. 2006;30(12):1561-156917122512PubMedGoogle ScholarCrossref
16.
Sjo OH, Berg M, Merok MA,  et al.  Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors.  J Surg Oncol. 2011;104(7):792-79721547915PubMedGoogle ScholarCrossref
17.
Yates MS, Meyer LA, Deavers MT,  et al.  Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA -associated tumorigenesis.  Cancer Prev Res (Phila). 2011;4(3):463-47021278312PubMedGoogle ScholarCrossref
18.
Menczer J, Chetrit A, Barda G,  et al.  Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women.  Gynecol Oncol. 2003;88(1):58-6112504628PubMedGoogle ScholarCrossref
19.
Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.  Am J Surg Pathol. 2009;33(8):1125-113619440148PubMedGoogle ScholarCrossref
20.
Grant DJ, Moorman PG, Akushevich L, Palmieri RT, Bentley RC, Schildkraut JM. Primary peritoneal and ovarian cancers: an epidemiological comparative analysis.  Cancer Causes Control. 2010;21(7):991-99820309725PubMedGoogle ScholarCrossref
21.
Laki F, Kirova YM, This P,  et al; IC-BOCRSG (Institut Curie–Breast Ovary Cancer Risk Study Group).  Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.  Cancer. 2007;109(9):1784-179017351952PubMedGoogle ScholarCrossref
22.
Finch A, Metcalfe K, Lui J,  et al.  Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.  Clin Genet. 2009;75(3):220-22419263514PubMedGoogle ScholarCrossref
23.
Finch A, Beiner M, Lubinski J,  et al; Hereditary Ovarian Cancer Clinical Study Group.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation.  JAMA. 2006;296(2):185-19216835424PubMedGoogle ScholarCrossref
24.
Scheuer L, Kauff N, Robson M,  et al.  Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.  J Clin Oncol. 2002;20(5):1260-126811870168PubMedGoogle ScholarCrossref
25.
Olivier RI, van Beurden M, Lubsen MA,  et al.  Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.  Br J Cancer. 2004;90(8):1492-149715083174PubMedGoogle ScholarCrossref
26.
Kauff ND, Satagopan JM, Robson ME,  et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.  N Engl J Med. 2002;346(21):1609-161512023992PubMedGoogle ScholarCrossref
27.
Rebbeck TR, Lynch HT, Neuhausen SL,  et al; Prevention and Observation of Surgical End Points Study Group.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.  N Engl J Med. 2002;346(21):1616-162212023993PubMedGoogle ScholarCrossref
28.
Powell CB, Chen LM, McLennan J,  et al.  Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.  Int J Gynecol Cancer. 2011;21(5):846-85121670699PubMedGoogle ScholarCrossref
29.
Maehle L, Apold J, Paulsen T,  et al.  High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.  Clin Cancer Res. 2008;14(22):7569-757319010876PubMedGoogle ScholarCrossref
30.
Domchek SM, Friebel TM, Singer CF,  et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.  JAMA. 2010;304(9):967-97520810374PubMedGoogle ScholarCrossref
31.
Rutter JL, Wacholder S, Chetrit A,  et al.  Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.  J Natl Cancer Inst. 2003;95(14):1072-107812865453PubMedGoogle ScholarCrossref
32.
Kauff ND, Domchek SM, Friebel TM,  et al.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 - and BRCA2 -associated breast and gynecologic cancer: a multicenter, prospective study.  J Clin Oncol. 2008;26(8):1331-133718268356PubMedGoogle ScholarCrossref
33.
Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.  Gynecol Oncol. 2005;97(2):457-46715863145PubMedGoogle ScholarCrossref
34.
Rhiem K, Foth D, Wappenschmidt B,  et al.  Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.  Arch Gynecol Obstet. 2011;283(3):623-62720428881PubMedGoogle ScholarCrossref
35.
Bellera CA, MacGrogan G, Debled M, de Lara CT, Brouste V, Mathoulin-Pélissier S. Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer.  BMC Med Res Methodol. 2010;10:2020233435PubMedGoogle ScholarCrossref
36.
Crowther MJ, Riley RD, Staessen JA, Wang J, Gueyffier F, Lambert PC. Individual patient data meta-analysis of survival data using Poisson regression models.  BMC Med Res Methodol. 2012;12:3422443286PubMedGoogle ScholarCrossref
37.
Lawless JF. Statistical Models and Methods for Lifetime Data. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2003
38.
Schluchter MD. Methods for the analysis of informatively censored longitudinal data.  Stat Med. 1992;11(14-15):1861-18701480878PubMedGoogle ScholarCrossref
39.
Piver MS. Prophylactic oophorectomy: reducing the US death rate from epithelial ovarian cancer: a continuing debate.  Oncologist. 1996;1(5):326-33010388011PubMedGoogle Scholar
40.
Casey MJ, Bewtra C. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.  Fam Cancer. 2004;3(3-4):265-28115516851PubMedGoogle ScholarCrossref
41.
Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk.  Eur J Hum Genet. 2009;17(11):1381-138519367322PubMedGoogle ScholarCrossref
42.
Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.  Fam Cancer. 2009;8(1):23-2818758995PubMedGoogle ScholarCrossref
43.
Genadry R, Poliakoff S, Rotmensch J, Rosenshein NB, Parmley TH, Woodruff JD. Primary, papillary peritoneal neoplasia.  Obstet Gynecol. 1981;58(6):730-7347312239PubMedGoogle Scholar
44.
Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.  Am J Obstet Gynecol. 2006;194(6):1702-170916731090PubMedGoogle ScholarCrossref
45.
Arienti C, Tesei A, Verdecchia GM,  et al.  Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.  J Transl Med. 2011;9:9421689426PubMedGoogle ScholarCrossref
46.
Gourley C, Michie CO, Roxburgh P,  et al.  Increased incidence of visceral metastases in Scottish patients with BRCA1/2 -defective ovarian cancer: an extension of the ovarian BRCAness phenotype.  J Clin Oncol. 2010;28(15):2505-251120406939PubMedGoogle ScholarCrossref
47.
Eitan R, Soslow R, Lin O,  et al.  The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy.  Gynecol Oncol. 2006;102(2):315-31816430946PubMedGoogle ScholarCrossref
48.
Lo NS, Sarr MG. Mucinous cystadenocarcinoma of the appendix: the controversy persists: a review.  Hepatogastroenterology. 2003;50(50):432-43712749241PubMedGoogle Scholar
49.
Giardiello FM, Offerhaus JG. Phenotype and cancer risk of various polyposis syndromes.  Eur J Cancer. 1995;31A(7-8):1085-10877576997PubMedGoogle ScholarCrossref
50.
Bussey HJ. Familial Polyposis Coli: Family Studies, Histopathology, Differential Diagnosis, and Results of Treatment. Baltimore, MD: Johns Hopkins University Press; 1975
51.
Burt RW, Leppert MF, Slattery ML,  et al.  Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis.  Gastroenterology. 2004;127(2):444-45115300576PubMedGoogle ScholarCrossref
52.
Vasen HF, Wijnen JT, Menko FH,  et al.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.  Gastroenterology. 1996;110(4):1020-10278612988PubMedGoogle ScholarCrossref
53.
Stoffel E, Mukherjee B, Raymond VM,  et al.  Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.  Gastroenterology. 2009;137(5):1621-162719622357PubMedGoogle ScholarCrossref
54.
Aretz S, Uhlhaas S, Goergens H,  et al.  MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype.  Int J Cancer. 2006;119(4):807-81416557584PubMedGoogle ScholarCrossref
55.
Hearle N, Schumacher V, Menko FH,  et al.  Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.  Clin Cancer Res. 2006;12(10):3209-321516707622PubMedGoogle ScholarCrossref
56.
Coburn MC, Pricolo VE, DeLuca FG, Bland KI. Malignant potential in intestinal juvenile polyposis syndromes.  Ann Surg Oncol. 1995;2(5):386-3917496832PubMedGoogle ScholarCrossref
57.
Desai DC, Neale KF, Talbot IC, Hodgson SV, Phillips RK. Juvenile polyposis.  Br J Surg. 1995;82(1):14-177881943PubMedGoogle ScholarCrossref
58.
Chand M, Moore PJ, Clarke AD, Nash GF, Hickisk T. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation: a case report of primary papillary serous carcinoma presenting as sigmoid cancer.  World J Surg Oncol. 2007;5:10217850658PubMedGoogle ScholarCrossref
59.
Misdraji J. Appendiceal mucinous neoplasms: controversial issues.  Arch Pathol Lab Med. 2010;134(6):864-87020524864PubMedGoogle Scholar
60.
Howlader N, Noone AM, Krapcho M,  et al.  SEER Cancer Statistics Review, 1975-2009. eds National Cancer Institute website.http://seer.cancer.gov/csr/1975_2009_pops09/sections.html. Updated 2012. Accessed August 15, 2012
61.
Goodman MT, Shvetsov YB. Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact?  Int J Cancer. 2009;124(9):2231-223519127596PubMedGoogle ScholarCrossref
62.
Thomas RM, Sobin LH. Gastrointestinal cancer.  Cancer. 1995;75(1):(suppl)  154-1708000994PubMedGoogle ScholarCrossref
63.
Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence.  Am J Surg Pathol. 2009;33(10):1425-143919641451PubMedGoogle ScholarCrossref
64.
Hale DA, Molloy M, Pearl RH, Schutt DC, Jaques DP. Appendectomy: a contemporary appraisal.  Ann Surg. 1997;225(3):252-2619060580PubMedGoogle ScholarCrossref
65.
Salom EM, Schey D, Peñalver M,  et al.  The safety of incidental appendectomy at the time of abdominal hysterectomy.  Am J Obstet Gynecol. 2003;189(6):1563-156814710065PubMedGoogle ScholarCrossref
66.
O’Hanlan KA, Fisher DT, O’Holleran MS. 257 Incidental appendectomies during total laparoscopic hysterectomy.  JSLS. 2007;11(4):428-43118237505PubMedGoogle Scholar
Review
March 2013

Risk-Reducing Appendectomy and the Elimination of BRCA1 -Associated Intraperitoneal Cancer

Author Affiliations

Author Affiliations: Department of Surgery, Indiana University School of Medicine, and Surgical Service, Roudebush Veterans Affairs Medical Center, Indianapolis.

JAMA Surg. 2013;148(3):285-291. doi:10.1001/jamasurg.2013.1006
Abstract

Risk-reducing bilateral salpingo-oophorectomy (RRBSO) and risk-reducing mastectomy are widely used for BRCA1 and BRCA2 mutation carriers to reduce the risk of ovarian and breast cancer. To our knowledge, no risk-reduction therapy has addressed the BCRA1/2 carrier lifetime risk of intra-abdominal peritoneal carcinoma from an appendix source. We identified a BRCA1 carrier in a hereditary breast and ovarian cancer kindred who developed a low-grade malignant appendiceal mucocele 2 years after risk-reducing salpingo-oophorectomy. Our retrospective meta-analysis assessed the risk of intraperitoneal appendiceal cancer in BRCA1/2 carriers after RRBSO to determine whether elective risk-reduction appendectomy could reduce the incidence of intraperitoneal cancer. Data sources included the case report and 12 reports of BRCA1 and BRCA2 carriers after RRBSO with ovarian, fallopian tube, breast, and peritoneal cancer published from January 1, 1985, through April 30, 2012. Main outcome measures were nonovarian, non–fallopian tube, nonbreast, positive intra-abdominal peritoneal carcinoma in previously cancer-free BRCA1/2 carriers after RRBSO. The source of intraperitoneal cancer in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy is highly likely the appendix. Use of risk-reduction appendectomy with RRBSO in younger BRCA1/2 carriers may reduce lifetime risk of malignant tumor and eliminate intraperitoneal cancer.

×